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ORIGINAL ARTICLE
Pharmacokinetics of carprofen and firocoxib for medication control
in racing greyhounds
TH Morris,a,b* SW Paine,a PW Zahra,c EC Li,c,f SA Colgand and SL Karamatice
Animals used in sport should be treated as required to ensure
animal welfare but any such use of medication should also be
controlled to ensure integrity. Pharmacokinetic studies on groups
of six greyhounds were performed to measure plasma and urine
levels of carprofen and firocoxib to inform medication control
advice. Using the standard methodology for medication control
the Irrelevant Plasma Concentration was determined as 20 and
2 ng/mL for carprofen and firocoxib, respectively. The Irrelevant
Urine Concentration was also determined as 0.3 and 2 ng/mL for
carprofen and firocoxib, respectively. These Irrelevant Plasma
and Urine Concentrations will allow laboratory Screening Limits,
Detection Times and Withdrawal Time advice to be determined
and publicised by regulators of greyhound racing. The Screening
Limits will also inform Recommended Limits of Detection if
meat-containing residues of these medications are fed to
greyhounds.
Keywords carprofen; firocoxib; greyhound; pharmacokinetics;
racing
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Non-steroidal anti-inflammatory drugs (NSAIDs) areimportant therapeutic agents for animals used in sports.They act to reduce the biosynthesis of prostaglandins
(PG) by inhibiting cyclooxygenase (COX) which exists in two
isoforms, COX-1 and COX-2. Preferential activity against COX-2
may have fewer adverse effects due to mitigation of concurrent
COX-1 inhibition in dogs, with favourable COX1:2 ratios having
been reported for carprofen and firocoxib.1
Animals used in sport should be treated as required to ensure their
welfare, for example, with NSAIDs, but any such medication use
should also be controlled to ensure integrity. The accepted approach
for medication control of drugs used in animal sports, is the control
of analytical sensitivity based on administration studies, with urine
being the sample matrix of choice for medication control.2 For a
particular drug, it is especially important to understand the need for
an extended administration study that includes urine as well as
plasma sampling to allow contemporaneous plasma and urine levels
that fully define the terminal phases of drug excretion, with a lower
limit of drug detection in the part per billion range (ng/mL) that is
appropriate for the different perspectives between therapy and med-
ication control.3 In addition to the therapeutic use of NSAIDs in
dogs, the role of their exposure via feeding meat from animals that
contain residues of NSAIDs to greyhounds is an issue that dictates
the need for a limit of detection that is also appropriate for control
of these residues.
In Australia, carprofen is licensed for use in dogs, cats and horses,
in Europe it is also licensed for use in cattle. There have been a
number of studies that examined the levels of carprofen in the
plasma of dogs.4-9 None of these studies appeared to fully extend
into the terminal phase of excretion, they did not have limits of
quantification down to an appropriate range of 1 ng/mL, nor did
they measure urine levels. One study measured urinary levels of
carprofen in two greyhound dogs, finding it for up to 72 h with a
limit of quantification of approximately 0.1 ng/mL, but it did not
measure plasma levels.10
In Australia, firocoxib is licensed for use in dogs, in Europe it is
licensed for use in dogs and horses. There are limited published
studies of the pharmacokinetics of firocoxib in dogs. Plasma phar-
macokinetics have been reported for 32 h after administration, with
plasma levels at around 100 ng/mL at that time.11 A method for
quantifying firocoxib in canine urine with a limit of detection of
3.0 ng/mL did not report any pharmacokinetic data.12 No published
studies have been found that measured urine levels in dogs.
The aims of this study were: to characterise the plasma and the uri-
nary pharmacokinetics of two commonly used NSAIDs, carprofen
and firocoxib, for the purpose of medication control in racing grey-
hounds at doses relevant to their prescription for use by trainers of
racing greyhounds; ensure analytical detection extended into the
terminal phase and at a higher sensitivity than previous studies;
derive Irrelevant Plasma and Urine Concentrations; produce regula-
tory advice for greyhound racing nationally and internationally in
respect of both medication and meat residue control limits; and so
enable science-based advice to veterinarians prescribing for racing
greyhounds.
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Materials and methods
Animal care and use
Six greyhounds,13 three females, three males, in good health were
selected from the SCEC research colony for inclusion in each study.
They were fed a commercial dry dog food (Dogpro PLUS Working
Dog, Hypro Petcare Pty. Ltd., Wilberforce, NSW, Australia) twice
daily with an additional portion of fresh knackery meat (Luddenham
Pet Meat, Luddenham, NSW, Aust), and had access to water at all
times. Drug administration preceded the morning feed, excluding the
final oral dose, which was given with a small amount of food. The
studies were conducted in accordance to the principles of the VICH
GCP guidelines.14 Ethics approval was obtained from the Secretary’s
Animal Care and Ethics Committee of the NSW Department of Pri-
mary Industries (Approval reference TRIM #15/1406(158)). The dogs
used in the carprofen study had received Flunixin meglumine (Ilium
Flunixil® Injection 50 mg/mL; Troy Laboratories Australia Pty. Ltd,
Glendenning NSW, Australia) intravenously on one occasion at the
label dose of 1 mg/kg (0.6 mg/kg flunixin free acid) 30 days previ-
ously.15 The dogs used in the firocoxib study had not been previously
used in other studies involving NSAIDs or any study within the pre-
vious 7 days.
Drug administrations and sample collections
Carprofen (Rimadyl® 50 mg/mL and Rimadyl® Tablets for Dogs
50 and 20 mg, Zoetis Australia Pty. Ltd., Rhodes, NSW, Australia)
was administered as 4 mg/kg single intravenous injection followed
1 day later by 4 mg/kg once daily oral administrations, utilising the
two tablet presentations that continued for 5 days. Three female and
three male animals were studied, with a mean bodyweight of 32.4 kg
and mean age of 3.8 years. Blood and urine were collected before
each daily drug administration over the first 6 days. Blood samples
were collected at 0, 0.25, 0.5, 1, 2, 4, 6, 8, 12, 24, 48, 72, 96 and
120 h, and then continued after the last administration at 120.25,
120.5, 121, 122, 124, 126, 128, 130, 132, 144, 168 and 192 h. Urine
samples were collected at 0, 2, 4, 6, 8, 10, 12, 24, 48, 72, 96 and
120 h, and then continued after the last administration at 122, 124,
126, 128, 130, 132, 144, 168 and 192 h.
Firocoxib (Previcox® 57 mg and 227 mg Hi-Select COX-2 Flavoured
Tablets, Merial Australia Pty. Ltd., Macquarie Park NSW, Australia)
was administered at a dose rate of 5 mg/kg orally once daily for
5 days, utilising the two tablet presentations. Three female and three
male animals were studied, with a mean bodyweight of 31.6 kg and
mean age of 3.8 years. Blood and urine were collected at times as for
the carprofen administration study.
The blood samples were heparinised and plasma obtained by centri-
fugation. All samples were then stored and transported at −20C
until analysis.
Sample preparation, chemical analysis, quantification,
calibration and quality control
Concentrations of carprofen and firocoxib were measured in the pre-
and post-administration plasma and urine samples by Racing Ana-
lytical Services Limited, Victoria, Australia.
Urine and plasma sample extraction. For carprofen in urine:
samples (3 mL) were hydrolysed by adding sodium hydroxide (2 M,
500 uL) and allowed to stand at room temperature for 30 min.
Sodium acetate buffer (1 mL) was then added and the pH adjusted
to 3. Samples were liquid/liquid extracted with hexane/dic-
hloromethane/ethyl acetate (40:30:30) for 15 min. After centrifuga-
tion, the organic layer was removed and washed with saturated
sodium bicarbonate (3 mL). Samples were centrifuged and the
organic layer removed and passed through anhydrous sodium sul-
phate. Extracts were evaporated to dryness under nitrogen at 60C.
Dried residues were methylated with diazomethane, followed by
reconstitution in ethyl acetate (100 μL).
For carprofen in plasma: samples (300 μL) were diluted with
deionised water (700 μL), followed by the addition of hydrochloric
acid (6.4%, 50 μL). Samples were then vortexed, followed by liquid/
liquid extraction with diethyl ether (4 mL) for 15 min. After centri-
fugation, the organic layer was removed, passed through anhydrous
sodium sulphate and evaporated to dryness under nitrogen at 60C.
Dried residues were methylated with diazomethane, followed by
reconstitution in ethyl acetate (100 μL).
For firocoxib in urine: samples (1 mL) were diluted with ammonium
acetate buffer (0.5 M, 3 mL) followed by enzyme hydrolysis. Samples
were adjusted to pH 6 and liquid/liquid extracted with hexane/dic-
hloromethane/ethyl acetate (40:30:30) for 15 min. After centrifuga-
tion, the organic layer was removed passed through anhydrous
sodium sulphate. Extracts were evaporated to dryness under nitrogen
at 60C, followed by reconstitution in formic acid (0.1%) and metha-
nol (95:5, 100 μL).
For firocoxib in plasma: samples (300 μL) were diluted with
deionised water (700 μL), followed by the addition of hydrochloric
acid (6.4%, 50 μL). Samples were then vortexed, followed by liquid/
liquid extraction with diethyl ether (4 mL) for 15 min. After centri-
fugation, the organic layer was removed, passed through anhydrous
sodium sulphate and evaporated to dryness under nitrogen at 60C.
Dried residues were reconstituted in formic acid (0.1%) and metha-
nol (95:5, 100 μL).
Sample analysis. Samples for carprofen analysis were processed by
gas chromatography mass spectrometry using an Agilent 7000B tri-
ple quadrupole mass spectrometer (Agilent, Santa Clara, CA, USA)
coupled to an Agilent 7890 gas chromatograph (Agilent). Chromato-
graphic separation was achieved using a SGE BPX5 (25 m × 0.2 mm
I.D. × 0.25 um film thickness) capillary column (SGE Analytical Sci-
ence, Ringwood, VIC, Aust) with helium as the carrier gas. Sample
injections (2 μL) were carried out in splitless mode with an inlet
temperature of 220C. The column oven was held at 75C for 1 min
and then ramped at a rate of 30C/min until a final temperature of
320C was reached. This temperature was held for 5 min. The carrier
gas was maintained at a constant flow rate of 1.2 mL/min. The mass
spectrometry (MS) was operated in electron ionisation mode with a
transfer line temperature of 300C and source temperature of 280C.
Carprofen was monitored using the transitions m/z 228 > m/z
193 (for quantitation), m/z 287 > m/z 228 and m/z 287 > m/z
193 (for identification). The internal standard, carprofen-d3, was
monitored using the transition m/z 231 > m/z 196.
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Samples for firocoxib analysis were processed by liquid chromatogra-
phy mass spectrometry using a Shimadzu 8050 triple quadruple mass
spectrometer (Shimadzu Corp., Kyoto, Japan) coupled to a Nexera
LC-30AD (Shimadzu Corp.) liquid chromatograph. Chromato-
graphic separation was achieved using a Poroshell 120 EC-C18 col-
umn (3 mm × 50 mm, 2.7 μm particle size) (Agilent Technologies).
The mobile phase consisted of 0.1% formic acid (A) and methanol
(B). The initial composition was 5% B, which was held for 0.3 min
and then ramped to reach 98% B at 3.5 min. This was held for
0.5 min before being returned to 50% B and equilibrated for 1.5 min.
The mass spectrometer was operated in multiple reaction monitoring
mode with positive polarity. Electrospray ionisation was carried out
with heater block, interface and dimorphite-DL (DL) temperatures
of 300, 300 and 300C, respectively. The nebulizer, heating and dry-
ing gas flow rates were 3, 5 and 15 L/min, respectively. Firocoxib was
monitored using the precursor ion m/z 337.1 and daughter ions m/z
265.1 (for quantitation), m/z 237.1 and m/z 130.1 (for identification).
The internal standard, Firocoxib-d4, was monitored using the transi-
tion m/z 341.1 > m/z 265.1.
Calibration and quality control. Calibration and quality control
samples for carprofen were used in the range of 2.5–1000 ng/mL for
urine and 1–1000 ng/mL plasma, and the methods were shown to be
linear with correlation coefficients greater than 0.99. The urine and
plasma methods produced a lower limmit of quantification (LLOQ)
of 2.5 and 1 ng/mL respectively, and were shown to be accurate and
reproducible with acceptable inter-batch variability of precision and
accuracy. The accuracy of the urine method was demonstrated to be
7.6% at LLOQ, and the precision 6.7% at LLOQ. The accuracy of the
plasma method was demonstrated to be 19.2% at LLOQ, and the
precision 4.3% at LLOQ.
Calibration and quality control samples for firocoxib were used in the
range of 2.5–1000 ng/mL for urine and 1–1000 ng/mL plasma, and
the methods were shown to be linear with correlation coefficients
greater than 0.99. The urine and plasma methods produced a LLOQ
of 2.5 and 1 ng/mL respectively, and were shown to be accurate and
reproducible with acceptable inter-batch variability of precision and
accuracy. The accuracy of the urine method was demonstrated to be
2.7% at LLOQ, and the precision 11.6% at LLOQ. The accuracy of the
plasma method was demonstrated to be 2.7% at LLOQ, and the preci-
sion 15.1% at LLOQ.
Urine pH was measured for carprofen and firocoxib, with a pH
meter (SevenEasy, Mettler Toledo, Schwerzenbach, Switzerland).
Pharmacokinetic analysis
Phoenix WinNonlin 7.0 (Pharsight Corporation, Cary, NC, USA)
was used for; a non-compartmental analysis of the plasma data for
firocoxib; a 2-compartmental pharmacokinetic analysis for the
0–24 h plasma data for carprofen; a non-compartmental analysis for
the last oral dose of carprofen from 120–192 h – in order to deter-
mine average steady-state plasma concentrations and terminal half-
life. Phoenix WinNonlin 7.0 (Pharsight Corporation) was used to
compute the area under the urine carprofen concentration-time
curve, a measure of carprofen exposure in the urine, which was com-
pared to the time weighted average urine pH for each dog using a
non-compartmental approach. Both parametric (student t-test) and
non-parametric (Mann-Whitney) tests were used to determine any
statistical differences in pharmacokinetic parameters between male
and female dogs.
Effective plasma concentrations were calculated by dividing the stan-
dard dose (per dosing interval) by the plasma clearance (per dosing
interval), a safety factor was then applied to derive an irrelevant
plasma concentration, and finally an irrelevant urine concentration
derived from applying the steady-state urine to plasma concentration
ratio.3
Results
Carprofen
Following an intravenous administration, continued 1 day later by
five once daily oral administrations, plasma carprofen concentrations
rapidly peaked and then declined rapidly over 4 h, and after the last
administration then progressed into a longer terminal phase. Each
pre-dose plasma concentration between 24 and 120 h showed no sig-
nificant accumulation (Figure 1A). Plasma pharmacokinetic parame-
ters for carprofen are summarised in Tables 1 and 2 with further
information in corresponding tables in the supplementary material.
The average bioavailability for the last oral dose relative to the IV
dose is 102%, that is, complete absorption of carprofen via the oral
route. Urine carprofen concentrations after IV administration reach
a peak at 4 h before progressing into a decay phase (Figure 1B. Each
pre-dose urine concentrations between 24 and 120 h showed no sig-
nificant accumulation. After the last oral administration levels peak
and decline in a similar manner to the intravenous terminal phase.
In plasma, all samples were above the LLOQ, and a single sample
from one of the six dogs was not obtained at 120 h after the final
carprofen administration. In urine, all samples were above the
LLOQ, and two samples from the six dogs could not be obtained at
2 h after the final drug administration and at 10 h after the final drug
administration in another dog. This latter dog was withdrawn late in
the study due to pyrexia requiring treatment, so the last sample at
72 h after the final drug administration was not obtained. There
appears to be no relationship between the carprofen exposure in
urine and the average urine pH (Figure S1). There were no statistical
differences between male and female dogs for the pharmacokinetic
(PK) parameters determined for carprofen. The computed effective
plasma concentration (EPC), Irrelevant Plasma Concentration (IPC),
Irrelevant Urine Concentration (IUC) and corresponding Detection
Times for carprofen are given in Table 3.
Firocoxib
Following oral administration once daily for 6 days to five grey-
hounds, plasma firocoxib concentrations increase rapidly over 4–8 h
before declining. There appears to be no accumulation of firocoxib
upon once daily dosing as shown by the immediate pre-dose concen-
trations between 24 and 120 h (Figure 2A). Plasma pharmacokinetic
parameters for firocoxib are summarised in Table 4 with further
information in the corresponding table in the supplementary mate-
rial. Urine firocoxib concentrations also peak within 4–8 h before
declining in a similar manner to the plasma pharmacokinetics with
urine concentrations generally mirroring those of plasma
(Figure 2B). In plasma, firocoxib was below the LLOQ in two of the
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five dogs 168 h after the last drug administration. In urine, firocoxib
was below the LLOQ in one dog 168 h after the last drug administra-
tion, in three dogs 192 h after the last drug administration, and in the
remaining dog 216 h after the last drug administration. The data from
one dog were removed from the plasma PK analysis as no samples were
taken after the first 24 h due to it being excluded from the study due to
Figure 1. (A) Plasma concentrations
in ng/mL of carprofen following a
4 mg/kg single intravenous injection
followed 1 day later by 4 mg/kg five
once daily oral administrations to
6 greyhounds, (B) urine concentra-
tions in ng/mL of carprofen following
a 4 mg/kg single intravenous injec-
tion followed 1 day later by 4 mg/kg
five once daily oral administrations
to 6 greyhounds,
Table 1. Plasma pharmacokinetic parameters for carprofen following a 4 mg/kg single intravenous injection fitted to a 2 compartmental pharmaco-
kinetic model
Data from 6 greyhounds V1 (L/kg) V2 (L/kg) First phase HL (h) Terminal HL (h) MRT (h) Vss (L/kg) CL (mL/min/kg)
Mean 0.098 0.066 1.11a 8.49a 11.17 0.16 0.26
Median 0.100 0.064 0.99 7.94 9.92 0.17 0.26
a Geometric mean.
CL is the plasma clearance for carprofen; HL are the respective half-lives of the first and second, terminal, decay phases; MRT is the mean resi-
dence time (average time spent in animal) of carprofen; V1 and V2 are the physiological volumes of each respective compartment; Vss is the
steady-state volume of distribution for carprofen.
Table 2. Plasma pharmacokinetic oral parameters of carprofen following the last oral dose (120–192 h) using a non-compartmental PK model.
AUC120-144 and AUC120-∞ are the area under the plasma curve for 120–144 h (24 h post last dose) and 120-infinity hours, respectively
Data from 6 greyhounds AUC120-144 (ng h/mL) AUC120-∞ (ng h/mL) HL (h)
Mean 317,893 378,650 7.63a
Median 307,855 369,493 7.50
a Geometric mean.
HL, half-life of the terminal phase.
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an injury unrelated to the study (a fight wound from another dog). The
AUC for the first 24 h in the case of this dog was approximately 2 times
higher than the AUC120-144 for the other dogs. There were no statistical
differences between male and female dogs for the PK parameters deter-
mined for firocoxib. The computed EPC, IPC, IUC and corresponding
Detection Times for firocoxib are given in Table 5.
Discussion
Carprofen
Pharmacokinetic parameters and excretion profiles in this study
were broadly similar to previous studies for plasma.4-9 and also to
the limited urine data.10 The lack of a relationship between the
carprofen exposure in urine and the average urine pH is not surpris-
ing as the pH range is narrow (5.4–6.6) and higher than the pKa.
The pH range is lower than the pH of blood suggesting that the neu-
tral form of carprofen dominates in urine leading to greater
reabsorption of carprofen back into blood. This will lead to lower
urine levels of carprofen relative to the situation where urine pH is
neutral or alkaline. Conversely, a greyhound with sustained neutral
to alkaline urine may have a higher concentration of carprofen in
their urine compared to the levels observed in this study.
The pre-dose plasma samples had no detectable levels of carprofen,
as expected as in Australia carprofen is licensed for use in dogs, cats
and horses, but not in other farm livestock. In Europe, it is also
licensed for use in cattle with the EU MRL for carprofen in bovine
being 500 μg/kg for muscle and 1000 μg/kg for liver/kidney.16
Assuming that a greyhound fed meat eats up to 600 g of meat per
day at a level of 500 μg/kg then that would be equivalent of
Table 3. Computed EPC, IPC, IUC and corresponding detection times for
carprofen
Mean plasma clearance 0.26 mL/min/kg
Dosing interval 24 h
EPC 10,684 ng/mL
IPC 21 ng/mL
IPC on ordinal scale 20 ng/mL
Plasma detection time 103 h
Rss 0.015
IUC 0.32 ng/mL
IUC on ordinal scale 0.3 ng/mL (300 pg/mL)
Urine detection time 105 h
Figure 2. (A) Plasma concentrations
in ng/mL of firocoxib following six
5 mg/kg once daily oral administra-
tions to 6 greyhounds. Symbols on
each line, which are different
between lines, indicate the data
from individual animals. (B) Urine
concentrations in ng/mL of firocoxib
following six 5 mg/kg once daily
oral administrations to 6 grey-
hounds. Symbols on each line,
which are different between lines,
indicate the data from individual
animals.
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delivering 300 μg of carprofen. If the meat was eaten once per day
for a few weeks then accumulation of approximately 20% for
carprofen would occur. Therefore, the effective dose of carprofen
would be 360 μg or approximately 12 μg/kg Greyhound. This
administration study delivered 4 mg/kg (= 4000 μg/kg) of carprofen,
that is, 333 times higher than the 12 μg/kg from ingestion of meat.
Therefore, the expected plasma levels due to ingestion of cattle mus-
cle at 500 μg/kg carprofen, 24 h after the last feed, would be approxi-
mately 18 ng/mL and the expected urine levels would be 0.12 ng/
mL. The expected urine levels would be below the LLOQ for urine
and therefore not be detected, whereas the expected plasma levels of
18 ng/mL due to feed would be detected. However, 18 ng/mL is
comparable to the Irrelevant Plasma Concentration (see below) of
20 ng/mL and theoretically there is the possibility of the limit being
exceeded. However, this would only occur if the meat contained the
highest level of the MRL when animal byproducts from treated ani-
mals are fed.
Firocoxib
The plasma concentrations of firocoxib are moderately higher as
compared to the information previously available where plasma con-
centrations were measured for up to 32 h.11 In the present study, the
AUC120-144 was 18,923 ng h/mL, whereas AUC 0–24 is reported as
4630 ng h/m,17 although for this latter AUC it is not stated whether
this is for a single administration value or the AUC of the dosing
interval for multiple administrations. This Summary of Product
Characteristics17 states the tablets can be administered with or
without food, the last dose was given with a small amount of food in
the present study, but the product assessment,18 states feeding is
unlikely to impact on the bioavailability of firocoxib. In the present
study, the half-life of the terminal phase was 6.5 h, as compared to
the elimination half-life of 7.59 h reported in the Summary of Prod-
uct Characteristics.17 As also found by Biddle (personal communica-
tion) hydroxyfirocoxib and desalkyl firocoxib are reported here as
urinary metabolites and this information on these metabolites in the
dog, which is not readily obtainable elsewhere, can be useful as evi-
dence of direct exposure, metabolism, and excretion if there is chal-
lenge on this aspect in sporting regulatory investigations. As
firocoxib is a neutral molecule and therefore does not ionise then
any changes in urine pH will have no effect on the urine pharmaco-
kinetics thus reducing variability.
The half-life of firocoxib in horses is 64.5 h with an EU MRL of
10 μg/kg for muscle and 60 μg/kg for liver.18 Assuming that a Grey-
hound fed meat eats up 600 g of meat per day at a level of 10 μg/kg
then that would be equivalent of delivering 6 μg of firocoxib. If the
meat was eaten once per day for a few weeks then accumulation of
approximately 8% for firocoxib would occur. Therefore, the effective
dose of firocoxib would be 6.5 μg or approximately 0.22 μg/kg. This
administration study delivered 5 mg/kg (= 5000 μg/kg) of firocoxib,
that is, 22,727 times higher than 0.22 μg/kg from ingestion of meat.
Therefore, the expected plasma levels due to ingestion of horse mus-
cle at 10 μg/kg firocoxib, 24 h after the last feed, would be approxi-
mately 23 pg/mL and the expected urine levels would be 12 pg/mL.
The expected urine levels would be below the LLOQ for urine and
therefore not be detected, whereas the expected plasma levels of
23 pg/mL due to feed may be detected. However, 23 pg/mL is much
lower than the Irrelevant Plasma Concentration (see below) of 2 ng/
mL and therefore will not lead to a positive finding.
Both these studies yielded adequate data, especially combining
plasma and urine levels for the first time, to inform medication con-
trol in racing greyhounds.
Medication control calculations
Using the standard methodology for medication control,3 the IPC
was determined as 20 and 2 ng/mL for carprofen and firocoxib,
respectively. The IUC was also determined as 0.3 and 2 ng/mL for
carprofen and firocoxib, respectively. Extrapolation for the terminal
phase was used for carprofen computations. The calculations for
Table 4. Pharmacokinetic parameters of firocoxib following oral administration of 5 mg/kg once per day for 6 days to 6 greyhounds using a non-
compartmental PK model
Data from 6 greyhounds AUC120-144 (ng h/mL) AUC120-∞ (ng h/mL) Terminal HL (h)
Mean 18,923 22,313 6.5a
Median 19,392 21,018 6.5
a Geometric mean.
AUC120-144 and AUC120-∞, the area under the plasma curve for 120–144 h (24 h post last dose) and 120-infinity hours, respectively; HL, half-life
of the terminal phase.
Table 5. Computed EPC, IPC, IUC and corresponding detection times for
firocoxib
Mean AUC120-144 18,923 ng h/mL
Dosing interval 24 h
EPC 788 ng/mL
IPC 1.6 ng/mL
IPC on ordinal scale 2 ng/mL
Plasma detection time 96 h
Rss 1
IUC 1.6 ng/mL
IUC on ordinal scale 2 ng/mL
Urine detection time 96 h
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these determinations are provided in the on-line supplementary
material.
The actual screening limit (SL), being the reporting levels used by
the analytic laboratories, and detection time (DT), being the time
after drug administration when the SL is not exceeded, as deter-
mined and publicised by regulators will not necessarily be absolutely
based on these Irrelevant Concentrations.19 Regulatory Risk Manage-
ment is not a scientific exercise but it should be scientifically sound,
and the SL may be (slightly) higher or lower than the IPC/IUC to
take into account other relevant factors other than residual drug effi-
cacy as the common goal to achieve harmonisation.20 For example,
it is reported from the efficacy studies completed during the registra-
tion process of firocoxib that the threshold for effect was approxi-
mately 100 ng/mL for the dog,11 and the contrast with the calculated
IPC of 2.0 ng/mL shows the different perspectives between therapy
and medication control. The carprofen IC50 in the plasma of dogs is
2.7 μg/mL,21 again in contrasting perspective with the calculated IPC
of 20 ng/mL.
The DT, as issued by the regulator is a regulatory decision based on
experimental data, whereas a withdrawal time (WT) is a recommen-
dation and, as such, is a matter for professional judgement of the
treating veterinarian. The WT should be longer than the DT because
the WT should take into account the impact of all sources of animal
variability (age, sex, breed, training, racing, etc.) and those of the
medicinal product actually administered.13
Given that dogs are fed meat, and if this contains drug residues, a
regulatory SL for medication control of carprofen and firocoxib,
derived from the IPC and IUC, can also serve as a Recommended
Limit of Detection for drug residues when feeding animal
byproducts.19
Conclusion
These administration studies characterised the plasma and the uri-
nary pharmacokinetics of carprofen and firocoxib, with sufficient
duration and sensitivity to enable the IPCs and IUCs to be deter-
mined after the exposure of greyhounds to clinical doses of
carprofen and firocoxib. This information will allow greyhound reg-
ulators to provide regulatory advice for greyhound racing in respect
of both a SL for medication control and a Recommended Limit of
Detection for drug residues if meat containing such residues is fed,
and for veterinarians to advise a WT.
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Additional Supporting Information may be found in the online ver-
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wiley.com/doi/10.1111/avj.13014/suppinfo.
Data S1. Supplementary Information.
Figure S1. Area under the urine carprofen concentration-time curve
versus time weighted average urine pH for each dog. Dotted line rep-
resents pKa of carprofen (4.3).
(Accepted for publication 6 August 2020)
Australian Veterinary Journal © 2020 The Authors. Australian Veterinary Journal published by John Wiley & Sons Australia, Ltd on behalf of Australian Veterinary Association.8
SMALL ANIMALS
SM
AL
L
AN
IM
AL
S
